{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:37:43Z","timestamp":1769701063170,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Misr International University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of green methods of analysis has recently become a global trend in analytical chemistry, especially in routine HPLC analysis. This study presents a sensitive and economic green HPLC method with fluorescence detection for the simultaneous determination of sacubitril and valsartan in bulk, and pharmaceutical dosage forms in spiked human plasma using ibuprofen as an internal standard. Analysis was performed on a C18 column (150\u00a0mm \u00d7 4.6\u00a0mm, 5\u00a0mm) at ambient temperature with isocratic elution using 30 mM phosphate (pH 2.5) and ethanol in a ratio of (40:60 v\/v) at a flow rate of 1.0 mL\/min. The fluorescence detector was programmed for excitation and emission wavelengths from 0 to 3.2\u00a0min, where \u03bb\n                    <jats:sub>Excitation<\/jats:sub>\n                    \u2009=\u2009250.0\u00a0nm and \u03bb\n                    <jats:sub>Emission<\/jats:sub>\n                    \u2009=\u2009380.0\u00a0nm. Then the \u03bb\n                    <jats:sub>Emission<\/jats:sub>\n                    was changed to 320.0\u00a0nm from 3.2 to 5.2\u00a0min while the \u03bb\n                    <jats:sub>Excitation<\/jats:sub>\n                    was not changed. After 5.2\u00a0min, the \u03bb\n                    <jats:sub>Excitation<\/jats:sub>\n                    and \u03bb\n                    <jats:sub>Emission<\/jats:sub>\n                    were changed to 220.0 and 289.0\u00a0nm, respectively. Validation of the proposed method was performed in accordance with the ICH guidelines. The method showed good linearity for sacubitril and valsartan in the concentration ranges of 0.035 to 2.205\u00a0\u00b5g\/mL and 0.035 to 4.430\u00a0\u00b5g\/mL, respectively. The proposed method was proven eco-friendly and applicable for routine analysis of the studied drugs in human plasma through assessment by the Analytical Eco-Scale, AGREE, the complex GAPI, the AGSA, the CaFRI, the RGBfast and the Click Analytical Chemistry Index methods.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-23181-x","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:00:51Z","timestamp":1762254051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A sensitive green HPLC-fluorescence method for simultaneous analysis of sacubitril and valsartan in pure forms, pharmaceutical dosage form and human plasma"],"prefix":"10.1038","volume":"15","author":[{"given":"Lubna Ahmed","family":"Kormod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha A.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira M.","family":"Kessiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"17","key":"23181_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"A Heidenreich Paul","year":"2022","unstructured":"Heidenreich Paul, A. et al. Guideline for the management of heart failure. J. Am. Coll. Cardiol. 79 (17), 263\u2013421 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"23181_CR2","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1002\/ehf2.14097","volume":"9","author":"A Abdin","year":"2022","unstructured":"Abdin, A. et al. Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail. 9 (6), 3737\u20133750 (2022).","journal-title":"ESC Heart Fail."},{"issue":"7229","key":"23181_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/bmj.320.7229.236","volume":"320","author":"RD Watson","year":"2000","unstructured":"Watson, R. D., Gibbs, C. R. & Lip, G. Y. ABC of heart failure. Clinical features and complications. BMJ 320 (7229), 236\u2013239 (2000).","journal-title":"BMJ"},{"issue":"10","key":"23181_CR4","first-page":"404","volume":"3","author":"J Easa","year":"2021","unstructured":"Easa, J., Easa, N., Chappell, J. & Warriner, D. Understanding the Pharmacology of heart failure. J. Prescr Pract. 3 (10), 404\u2013410 (2021).","journal-title":"J. Prescr Pract."},{"issue":"6","key":"23181_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5603\/CJ.a2016.0063","volume":"23","author":"EH Howell","year":"2016","unstructured":"Howell, E. H. & Cameron, S. J. Neprilysin inhibition: A brief review of past Pharmacological strategies for heart failure treatment and future directions. Cardiol. J. 23 (6), 591\u2013598 (2016).","journal-title":"Cardiol. J."},{"issue":"1","key":"23181_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bcpt.12453","volume":"118","author":"M Andersen","year":"2015","unstructured":"Andersen, M., Simonsen, U., Wehland, M., Pietsch, J. & Grimm, D. Valsartan\/Sacubitril - A possible new treatment for hypertension and heart failure. Basic. clin. pharmacol. toxicol. 118 (1), 14\u201322 (2015).","journal-title":"Basic. clin. pharmacol. toxicol."},{"key":"23181_CR7","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 60846, Valsartan. (2025). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Valsartan. Accessed Aug. 19."},{"key":"23181_CR8","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 9811834, Sacubitril. (2025). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Sacubitril. Accessed Aug. 19."},{"issue":"2","key":"23181_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.21608\/aprh.2018.5825","volume":"2","author":"K Attia","year":"2018","unstructured":"Attia, K., Nassar, M., El-Olemy, A. & Ramzy, S. Simultaneous spectrophotometric determination of sacubitril and Valsartan in their recently approved pharmaceutical Preparation. J. Adv. Pharm. Res. 2 (2), 133\u2013141 (2018).","journal-title":"J. Adv. Pharm. Res."},{"key":"23181_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.saa.2017.12.050","volume":"193","author":"MS Eissa","year":"2018","unstructured":"Eissa, M. S. & Alamein, A. A. Innovative spectrophotometric methods for simultaneous Estimation of the novel two-drug combination: Sacubitril\/Valsartan through two manipulation approaches and a comparative statistical study. Spectrochim Acta Mol. Biomol. Spectrosc. 193, 365\u2013374 (2018).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"issue":"8","key":"23181_CR11","first-page":"1417","volume":"32","author":"MAA Ragab","year":"2017","unstructured":"Ragab, M. A. A., Galal, S. M., Korany, M. A. & Ahmed, A. R. First derivative emission spectrofluorimetric method for the determination of LCZ696, a newly approved FDA supramolecular complex of Valsartan and sacubitril in tablets. Lumin 32 (8), 1417\u20131425 (2017).","journal-title":"Lumin"},{"key":"23181_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.saa.2021.119748","volume":"256","author":"RM Youssef","year":"2021","unstructured":"Youssef, R. M., El-Nahass, S. A., Soliman, S. A. & Younis, S. E. Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and sacubitril in LCZ696 tablets. Spectrochim Acta Mol. Biomol. Spectrosc. 256, 1\u20137 (2021).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"issue":"2","key":"23181_CR13","first-page":"11","volume":"8","author":"AMAA Alamein","year":"2018","unstructured":"Alamein, A. M. A. A. Validated Eco-Friendly chromatographic methods for simultaneous determination of sacubitril and Valsartan in spiked human plasma and in pharmaceutical formulation. J. Appl. Pharm. Sci. 8 (2), 11\u201317 (2018).","journal-title":"J. Appl. Pharm. Sci."},{"key":"23181_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/chromsci\/bmy021","volume":"56","author":"MAA Ragab","year":"2018","unstructured":"Ragab, M. A. A., Galal, S. M., Korany, M. A. & Ahmed, A. R. High performance thin-layer and high performance liquid chromatography coupled with photodiode array and fluorescence detectors for analysis of Valsartan and sacubitril in their supramolecular complex with quantitation of sacubitril-related substance in Raw material and tablets. J. Chromatogr. Sci. 56, 498\u2013509 (2018).","journal-title":"J. Chromatogr. Sci."},{"issue":"2","key":"23181_CR15","doi-asserted-by":"publisher","first-page":"e5550","DOI":"10.1002\/bmc.5550","volume":"37","author":"C Vijaykumar","year":"2023","unstructured":"Vijaykumar, C., Kumar, Y. R., Aparna, P. & Rao, P. S. P. Development and validation of a stability-indicating, single HPLC method for sacubitril-valsartan and their stereoisomers and identification of forced degradation products using LC-MS\/MS. Biomed. Chromatogr. 37 (2), e5550 (2023).","journal-title":"Biomed. Chromatogr."},{"issue":"1","key":"23181_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bmc.5240","volume":"36","author":"VB Subramanian","year":"2022","unstructured":"Subramanian, V. B. et al. Stability-indicating reversed-phase-HPLC method development and validation for sacubitril\/valsartan complex in the presence of impurities and degradation products: robustness by quality-by-design approach. Biomed. Chromatogr. 36 (1), 1\u201314 (2022).","journal-title":"Biomed. Chromatogr."},{"issue":"1","key":"23181_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10337-017-3425-9","volume":"81","author":"BA Moussa","year":"2018","unstructured":"Moussa, B. A., Hashem, H. M. A., Mahrouse, M. A. & Mahmoud, S. T. Experimental design approach in HPLC method development: application for the simultaneous determination of sacubitril and Valsartan in presence of their impurities and investigation of degradation kinetics. Chromatographia 81 (1), 139\u2013156 (2018).","journal-title":"Chromatographia"},{"issue":"6","key":"23181_CR18","first-page":"1728","volume":"7","author":"BS Rao","year":"2018","unstructured":"Rao, B. S., Reddy, M. V. & Bhatraju, S. R. Reverse phase stability indicating high performance liquid chromatographic method for determination of sacubitril and Valsartan in the presence of its stress degradation products. World J. Pharm. Pharm. Sci. 7 (6), 1728\u20131737 (2018).","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"8","key":"23181_CR19","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.52711\/0974-360X.2022.00607","volume":"15","author":"HP Priyanka Yadav","year":"2022","unstructured":"Priyanka Yadav, H. P. Stability indicating RP-HPLC method for simultaneous Estimation of Valsartan and sacubitril in pharmaceutical dosage form. Res. J. Pharm. Technol. 15 (8), 3627\u20133633 (2022).","journal-title":"Res. J. Pharm. Technol."},{"issue":"7","key":"23181_CR20","first-page":"7079","volume":"5","author":"J Afshan","year":"2018","unstructured":"Afshan, J. & Rizwan, S. H. Simultaneous Estimation of sacubitril and Valsartan in pharmaceutical dosage form in development and validation of stability indicating chromatographic method. Indo Am. J. Pharm. Sci. 5 (7), 7079\u20137087 (2018).","journal-title":"Indo Am. J. Pharm. Sci."},{"issue":"1","key":"23181_CR21","first-page":"17","volume":"4","author":"P Parthiban","year":"2017","unstructured":"Parthiban, P. New method development and validation for the simultaneous Estimation of sacubitril and Valsartan in a bulk and pharmaceutical dosage forms. Int. J. Res. 4 (1), 17\u201324 (2017).","journal-title":"Int. J. Res."},{"issue":"7","key":"23181_CR22","first-page":"1434","volume":"6","author":"CJ Patel","year":"2017","unstructured":"Patel, C. J., Mishra, S. & Patel, M. M. Simultaneous Estimation of sacubitril and Valsartan in pharmaceutical dosage form by development and validation of stability indicating chromatographic method. World J. Pharm. Pharm. Sci. 6 (7), 1434\u20131448 (2017).","journal-title":"World J. Pharm. Pharm. Sci."},{"issue":"5","key":"23181_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22159\/ijap.2017v9i5.19139","volume":"9","author":"S Mishra","year":"2017","unstructured":"Mishra, S., Patel, C. J. & Patel, M. M. Development and validation of stability indicating chromatographic method for simultaneous Estimation of sacubitril and Valsartan in pharmaceutical dosage form. Int. J. Appl. Pharm. 9 (5), 1\u20138 (2017).","journal-title":"Int. J. Appl. Pharm."},{"issue":"1","key":"23181_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22159\/ijap.2017v9i1.15448","volume":"9","author":"S Naazneen","year":"2016","unstructured":"Naazneen, S. & Sridevi, A. Development of assay method and forced degradation study of Valsartan and sacubitril by RP-HPLC in tablet formulation. Int. J. Appl. Pharm. 9 (1), 9\u201315 (2016).","journal-title":"Int. J. Appl. Pharm."},{"issue":"1","key":"23181_CR25","first-page":"79","volume":"2","author":"F Begum","year":"2016","unstructured":"Begum, F. & Rizwan, S. Stability indicating analytical method development and validation for Estimation of sacubitril and Valsartan in bulk and pharmaceutical dosage form using RP-HPLC. Int. J. Farmacia. 2 (1), 79\u201387 (2016).","journal-title":"Int. J. Farmacia"},{"issue":"9","key":"23181_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1039\/C7AY02523H","volume":"10","author":"L Zhou","year":"2018","unstructured":"Zhou, L. et al. A liquid chromatographic method for separation of sacubitril\u2013valsartan and their stereoisomeric impurities. Anal. Methods. 10 (9), 1046\u20131053 (2018).","journal-title":"Anal. Methods"},{"issue":"2","key":"23181_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7324\/JAPS.2020.102015","volume":"10","author":"P Prajapati","year":"2020","unstructured":"Prajapati, P., Bhayani, D. & Mehta, P. Development and validation of a stability indicating UHPLC method for Sacubitril\/Valsartan complex in the presence of impurities and degradation products. J. Appl. Pharm. Sci. 10 (2), 97\u2013107 (2020).","journal-title":"J. Appl. Pharm. Sci."},{"issue":"4","key":"23181_CR28","first-page":"279","volume":"10","author":"NM Gopal","year":"2017","unstructured":"Gopal, N. M. & Sridhar, C. RP-UPLC method for simultaneous Estimation of sacubitril and Valsartan in its bulk and tablet dosage form with force degadation studies. Int. J. ChemTech Res. 10 (4), 279\u2013287 (2017).","journal-title":"Int. J. ChemTech Res."},{"key":"23181_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bmc.5203","volume":"35","author":"BA Moussa","year":"2021","unstructured":"Moussa, B. A., Hashem, H. M. A., Mahrouse, M. A. & Mahmoud, S. T. Synchronized determination of sacubitril and Valsartan with some co-administered drugs in human plasma via UPLC-MS\/MS method using solid-phase extraction. Biomed. Chromatogr. 35, 1\u201312 (2021).","journal-title":"Biomed. Chromatogr."},{"issue":"3","key":"23181_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.5958\/0974-360X.2019.00168.9","volume":"12","author":"S Trefi","year":"2019","unstructured":"Trefi, S., Bitar, Y. & V\u00e9ronique, G. Separation and quantification of Sacubitril-Valsartan combination in tablets by a new Ion-pair HPLC. Res. J. Pharm. Tech. 12 (3), 1017\u20131022 (2019).","journal-title":"Res. J. Pharm. Tech."},{"issue":"A","key":"23181_CR31","first-page":"1996","volume":"8","author":"P Seetharamaiah","year":"2022","unstructured":"Seetharamaiah, P., Pappula, N., Rao, S. & Gowrisankar, D. Development and validation of new RP-HPLC method for the simultaneous Estimation of sacubitril and Valsartan in pharmaceutical dosage form. Int. J. Recent. Sci. Res. 8 (A), 1996\u20132001 (2022).","journal-title":"Int. J. Recent. Sci. Res."},{"issue":"5","key":"23181_CR32","first-page":"1004","volume":"6","author":"T Raju","year":"2017","unstructured":"Raju, T., Kumar, R., Ramachandran, D. & D.R. & Assay of Valsartan and sacubitril in combined dosage form by RP-HPLC (Method development and Validation). J. Appl. Chem. 6 (5), 1004\u20131011 (2017).","journal-title":"J. Appl. Chem."},{"issue":"10","key":"23181_CR33","first-page":"829","volume":"2","author":"M RAJA","year":"2021","unstructured":"RAJA, M., Naresh, D. & Kumar, G. V. RP-HPLC method for the simultaneous Estimation of sacubitril and Valsartan in bulk and tablet dosage form. Int. J. Res. Publ Rev. 2 (10), 829\u2013840 (2021).","journal-title":"Int. J. Res. Publ Rev."},{"issue":"1","key":"23181_CR34","first-page":"9","volume":"8","author":"Y Phalguna","year":"2018","unstructured":"Phalguna, Y., Nour, J., Indraja, N. & Kumar, S. G. Analytical method development and validation for the Estimation of sacubitril and Valsartan in combined pharmaceutical dosage forms by RP-HPLC. Asian J. Res. Pharm. Sci. 8 (1), 9\u201316 (2018).","journal-title":"Asian J. Res. Pharm. Sci."},{"issue":"9","key":"23181_CR35","first-page":"2201","volume":"10","author":"U Jyothi","year":"2018","unstructured":"Jyothi, U., Umadevi, P. & Stability Indicating RP-HPLC method for the simultaneous Estimation of sacubitril and Valsartan in drug product. J. Pharm. Sci. Res. 10 (9), 2201\u20132204 (2018).","journal-title":"J. Pharm. Sci. Res."},{"issue":"12","key":"23181_CR36","first-page":"640","volume":"4","author":"SK Godasu","year":"2017","unstructured":"Godasu, S. K. & Sreenivas, S. A. A new Rp-Hplc method for simultaneous Estimation of sacubitril and Valsartanin its bulk and tablet dosage form. Eur J. Biomed. Pharm Sci. 4 (12), 640\u2013645 (2017).","journal-title":"Eur J. Biomed. Pharm Sci"},{"issue":"9","key":"23181_CR37","first-page":"185","volume":"3","author":"V Swetha","year":"2017","unstructured":"Swetha, V., Parsad, S. M. & Indupriya, M. RP-HPLC method development and validation for the simultaneous Estimation of sacubitril and Valsartan in bulk and pharmaceutical dosage form. World j. Pharm. Life Sci. 3 (9), 185\u2013191 (2017).","journal-title":"World j. Pharm. Life Sci."},{"issue":"3","key":"23181_CR38","first-page":"262","volume":"6","author":"KH Patel","year":"2016","unstructured":"Patel, K. H., Luhar, S. V. & Narkhede, S. B. Simultaneous Estimation of sacubitril and Valsartan in synthetic mixture by RP-HPLC method. J. Pharm. Sci. Biosci. Res. 6 (3), 262\u2013269 (2016).","journal-title":"J. Pharm. Sci. Biosci. Res."},{"issue":"5","key":"23181_CR39","first-page":"1","volume":"6","author":"N Anjaneyulu","year":"2018","unstructured":"Anjaneyulu, N., Kishur, R. N., Kumar, M. R. & Sneha, G. Development and validation of A RP- HPLC method for the simultaneous Estimation of Valsartan and sacubitril in rat plasma. Global J. Pharm. Pharm. Sci. 6 (5), 1\u20136 (2018).","journal-title":"Global J. Pharm. Pharm. Sci."},{"key":"23181_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.microc.2018.07.021","volume":"143","author":"BA Moussa","year":"2018","unstructured":"Moussa, B. A., Hashem, H. M. A., Mahrouse, M. A. & Mahmoud, S. T. A validated RP-HPLC method for the determination of Rosuvastatin in presence of sacubitril\/valsartan in rat plasma: application to in vivo evaluation of OATP-mediated drug interaction potential between Rosuvastatin and sacubitril\/valsartan. Microchem J. 143, 31\u201338 (2018).","journal-title":"Microchem J."},{"key":"23181_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/10826076.2018.1436070","volume":"41","author":"M Attimarad","year":"2018","unstructured":"Attimarad, M., Nagaraja, S. H., Nair, A. B., Aldhubaib, B. E. & Katharigatta, V. N. Development of validated RP HPLC method with fluorescence detection for simultaneous quantification of sacubitril and Valsartan from rat plasma. J. Liq Chromatogr. Rel Technol. 41, 246\u2013252 (2018).","journal-title":"J. Liq Chromatogr. Rel Technol."},{"key":"23181_CR42","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/bmc.3707","volume":"30","author":"RH Chunduri","year":"2016","unstructured":"Chunduri, R. H. & Dannana, G. S. Development and validation of a reliable and rapid LC-MS\/MS method for simultaneous quantification of sacubitril and Valsartan in rat plasma and its application to a Pharmacokinetic study. Biomed. Chromatogr. 30, 1467\u20131475 (2016).","journal-title":"Biomed. Chromatogr."},{"key":"23181_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1755-5922.12183","volume":"34","author":"Z Kobalava","year":"2016","unstructured":"Kobalava, Z. et al. Pharmacodynamic and Pharmacokinetic profiles of Sacubitril\/Valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc. Ther. 34, 191\u2013198 (2016).","journal-title":"Cardiovasc. Ther."},{"key":"23181_CR44","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1039\/c0gc00918k","volume":"13","author":"RK Henderson","year":"2011","unstructured":"Henderson, R. K. et al. Expanding gsk\u2019s solvent selection guide \u2013 embedding sustainability into solvent selection starting at medicinal chemistry. Green. Chem. 13, 854\u2013862 (2011).","journal-title":"Green. Chem."},{"issue":"6","key":"23181_CR45","first-page":"1","volume":"7","author":"CK Singh","year":"2022","unstructured":"Singh, C. K. & Sacubitril Valsartan (Entresto): A review on development of analytical methods and its assessment in Pure, bulk Formulation, biological fluids and pharmaceutical Preparation. Int. J. Pharm. Sci. Med. 7 (6), 1\u201338 (2022).","journal-title":"Int. J. Pharm. Sci. Med."},{"issue":"1","key":"23181_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10717544.2023.2183816","volume":"30","author":"JG Song","year":"2023","unstructured":"Song, J. G. et al. Quantitative analysis of therapeutic proteins in biological fluids: recent advancement in analytical techniques. Drug Deliv. 30 (1), 1\u201320 (2023).","journal-title":"Drug Deliv"},{"key":"23181_CR47","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.4155\/bio.11.201","volume":"3","author":"NY Ashri","year":"2011","unstructured":"Ashri, N. Y. & Abdel-Rehim, M. Sample treatment based on extraction techniques in biological matrices. Bioanal 3, 2003\u20132018 (2011).","journal-title":"Bioanal"},{"key":"23181_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jchromb.2016.09.028","volume":"1043","author":"MM Moein","year":"2017","unstructured":"Moein, M. M., Beqqali, E., Abdel-Rehim, M. & A. & Bioanalytical method development and validation: critical concepts and strategies. J Chromatogr. B Analyt Technol. Biomed Life Sci. 1043, 3\u201311 (2017).","journal-title":"J Chromatogr. B Analyt Technol. Biomed Life Sci"},{"key":"23181_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0021-9673(98)00042-9","volume":"805","author":"CB Castells","year":"1998","unstructured":"Castells, C. B. & Castells, R. C. Peak distortion in reversed-phase liquid chromatography as a consequence of viscosity differences between sample solvent and mobile phase. J. Chromatogr. A. 805, 55\u201361 (1998).","journal-title":"J. Chromatogr. A"},{"key":"23181_CR50","unstructured":"Guidelines & Validation of Analytical Procedures Q2(R. 2), Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2024)."},{"key":"23181_CR51","unstructured":"Guidelines & Bioanalytical Method Validation and Study. : Sample Analysis. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use., Geneva, Switzerland, ICH-M10, (2022)."},{"key":"23181_CR52","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jchromb.2008.09.030","volume":"877","author":"P Araujo","year":"2009","unstructured":"Araujo, P. Key aspects of analytical method validation and linearity evaluation. J. Chrom B. 877, 2224\u20132234 (2009).","journal-title":"J. Chrom B"},{"key":"23181_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10408349891199356","volume":"29","author":"PT Anastas","year":"1999","unstructured":"Anastas, P. T. Green chemistry and the role of analytical methodology development. Crit. Rev. Anal. Chem. 29, 167\u2013175 (1999).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"23181_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka, A., Migaszewski, Z. M., Konieczka, P. & Namie\u015bnik, J. Analytical Eco-Scale for assessing the greenness of analytical procedures. Trends Anal. Chem. 37, 61\u201372 (2012).","journal-title":"Trends Anal. Chem."},{"key":"23181_CR55","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE-Analytical greenness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."},{"key":"23181_CR56","first-page":"1","volume":"10","author":"FR Mansour","year":"2024","unstructured":"Mansour, F. R., Omer, K. M. & P\u0142otka-Wasylka, J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. Green. Analyt Chem. 10, 1\u20134 (2024).","journal-title":"Green. Analyt Chem."},{"issue":"1","key":"23181_CR57","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13065-025-01486-2","volume":"19","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R. & Nowak, P. M. Introducing the carbon footprint reduction index (CaFRI) as a software-supported tool for greener laboratories in chemical analysis. BMC Chem. 19 (1), 121\u2013132 (2025).","journal-title":"BMC Chem."},{"key":"23181_CR58","first-page":"1","volume":"46","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R. et al. Analytical green star area (AGSA) as a new tool to assess greenness of analytical methods. Sustain. Chem. Pharm. 46, 1\u201310 (2025).","journal-title":"Sustain. Chem. Pharm."},{"key":"23181_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181, 204\u2013209 (2018).","journal-title":"Talanta"},{"issue":"21","key":"23181_CR60","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1039\/D1GC02318G","volume":"23","author":"J P\u0142otka-Wasylka","year":"2021","unstructured":"P\u0142otka-Wasylka, J. & Wojnowski, W. Complementary green analytical procedure index (ComplexGAPI) and software. Green. Chem. 23 (21), 8657\u20138665 (2021).","journal-title":"Green. Chem."},{"key":"23181_CR61","doi-asserted-by":"crossref","unstructured":"Mansour, F. R., P\u0142otka-Wasylka, J., Locatelli, M. & Modified, G. A. P. I. (eds) (MoGAPI) Tool and Software for the Assessment of Method Greenness: Case Studies and Applications. Analytica. 5(3). 451\u2013457 (2024).","DOI":"10.3390\/analytica5030030"},{"key":"23181_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.greeac.2024.100120","volume":"10","author":"PM Nowak","year":"2024","unstructured":"Nowak, P. M. & Arduini, F. RGBfast \u2013 A user-friendly version of the Red-Green-Blue model for assessing greenness and whiteness of analytical methods. Green. Anal. Chem. 10, 1\u20136 (2024).","journal-title":"Green. Anal. Chem."},{"key":"23181_CR63","first-page":"1","volume":"14","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R., Bedair, A. & Locatelli, M. Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods. Adv. Sample Prep. 14, 1\u201310 (2025).","journal-title":"Adv. Sample Prep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23181-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:03:03Z","timestamp":1762257783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23181"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23181-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable. The study involves the use of unidentifiable plasma bags purchased from Vacsera Co. (Egypt) that is considered a non-human subject, where the need for an ethical approval was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"38484"}}